Idaho IMPORTANT NOTICE **FLU EDITION**

Route to:

- ☐ Office Manager
- ☐ Medical Staff
- □ Nursing Staff
- ☐ Immunization
- Coordinator

An Immunization Update from the Idaho Immunization Program (IIP)

2012-2013 SEASONAL INFLUENZA VACCINE

Recommendations

The Advisory Committee on Immunization Practices (ACIP) recommendations for the prevention and control of seasonal influenza (2012-2013 influenza season) are as follows:

> "All persons 6 months of age and older are recommended to receive annual influenza vaccination."

The U.S. influenza vaccine for 2012-2013 will contain:

- A/California/7/2009 (H1N1)-like virus;
- A/Victoria/361/2011 (H3N2)-like virus;
- B/Wisconsin/1/2010-like virus (from the B/Yamagata lineage of viruses).

The H3N2 and B strains were not included in the 2011-2012 seasonal influenza vaccine. To permit time for production of protective antibody levels, healthcare providers should begin offering influenza vaccine as soon as it becomes available. Vaccination should be offered throughout the influenza season.

Supply

Production and distribution of seasonal influenza vaccine is never guaranteed. Each spring the IIP requests from the Centers for Disease Control and Prevention (CDC) the number of seasonal flu doses needed based upon population, estimated vaccine uptake, and available funding. The final number of doses made available to the IIP is dependent upon the contracts CDC secures with vaccine manufacturers as well as vaccine supply.

The requested 2012-2013 seasonal flu vaccine will be allocated to the IIP in waves from August through December. The IIP will distribute the influenza vaccine as it becomes available.

Ordering

The 2012-2013 seasonal influenza vaccine can be ordered from the IIP through the Immunization Reminder Information System (IRIS) beginning August 22, 2012. The pediatric influenza vaccine is listed in IRIS on the Create Orders screen.

- Influenza orders do not need to follow your ordering frequency.
- Orders may be placed for particular brands and/or presentations; however, if the brand requested is not available then the order will be denied and a fax will be sent indicating available brands or presentations.
- Orders that are reduced will not be tracked and filled at a later date. There will be no backorders.
- Current on-hand counts are reviewed before vaccine orders are approved (as with all vaccine orders). Stay current with entering doses of influenza vaccine administered into IRIS.

Vaccine Information Sheets

2012-2013 seasonal influenza vaccine information sheets (VIS) are available to order from the IIP. Please go to the IIP's website at www.immunizeidaho.com and click on the Resource Order Form link on the healthcare provider page.



Idaho IMPORTANT NOTICE Immunization Program FLU EDITION


- Mardial Chaff
- ☐ Medical Staff
- □ Nursing Staff□ Immunization

Coordinator

An Immunization Update from the Idaho Immunization Program (IIP)

Dose Recommendations

Influenza vaccine dosing algorithm for children aged 6 months through 8 years for the 2012-2013 influenza season:



For simplicity, this algorithm takes into consideration only doses of seasonal influenza vaccine received since July 1, 2010. This recommendation is harmonized with that of the American Academy of Pediatrics. Using this approach, children aged 6 months through 8 years need only 1 dose of vaccine in 2012-2013 if they received a total of 2 or more doses of seasonal vaccine since July 1, 2010. Children who did not receive a total of 2 or more doses of seasonal vaccine since July 1, 2010, require 2 doses in 2012-2013.

As an alternative approach in settings where vaccination history from before July 1, 2010, is available, if a child aged 6 months through 8 years is known to have received at least 2 seasonal influenza vaccines during any previous season, and at least 1 dose of a 2009(H1N1)-containing vaccine, then the child needs only 1 dose of the 2012-2013 vaccine. Using this approach, children aged 6 months through 8 years need only 1 dose of the 2012-2013 vaccine if they have received any of the following:

- 2 or more doses of seasonal influenza vaccine since July 1, 2010; or
- 2 or more doses of seasonal influenza vaccine before July 1, 2010, and 1 or more doses of monovalent 2009(H1N1) vaccine; or
- 1 or more doses of seasonal influenza vaccine before July 1, 2010, and 1 or more doses of seasonal influenza vaccine since July 1, 2010.

For additional information please refer to MMWR / August 17, 2012 / Vol. 61 / No. 32 or visit http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s cid=mm6132a3 e%0d%0a

RECOMMENDED PEDIATRIC INFLUENZA VACCINE

Available from the Idaho Immunization Program for the 2012-2013 Season*

VACCINE	TRADE NAME	Manufacturer	Presentation	MERCURY CONTENT (mcg Hg/0.5mL dose)	AGE GROUP	NUMBER OF DOSES	Route	NDC	CVX CODES (for electronic exports)
TIV	Fluzone [®]	Sanofi Pasteur	0.25mL pre- filled syringe	0	6-35 months	1 or 2	IM**	49281-0112-25	140
			0.5mL pre-filled syringe	0	≥ 36 months	1 or 2	IM**	49281-0112-50	140
			0.5mL vial	0	≥ 36 months	1 or 2	IM**	49281-0112-10	140
			5.0mL multi- dose vial	25	≥ 6 months	1 or 2	IM**	49281-0390-15	141
TIV	Fluvirin [®]	Novartis	0.5mL pre-filled syringe	< 1.0	<u>></u> 4 years	1 or 2	IM**	66521-0115-02	140
TIV	Fluarix [®]	GlaxoSmithKline	0.5mL pre-filled syringe	0	<u>></u> 3 years	1 or 2	IM**	58160-0879-52	140
TIV	Afluria®	CSL Biotherapies (distributed by Merck)	0.5mL pre-filled syringe	0	<u>></u> 9 years¶	1	IM**	33332-0012-01	140
LAIV	FluMist [®] §	MedImmune	0.2mL sprayer	0	2-18 years§§	1 or 2	IN	66019-0110-10	110

Abbreviations: TIV=trivalent inactivated vaccine; LAIV=live-attenuated influenza vaccine; IM=intramuscular injection; IN=intranasal.

¶ Age indication per package insert is \geq 5 years; however, the Advisory Committee on Immunization Practices recommends that Afluria not be used in children aged 6 months through 8 years because of increased risk of febrile reactions noted in this age group with CSL's 2010 Southern Hemisphere TIV. If no other age-appropriate, licensed inactive seasonal influenza vaccine is available for a child aged 5 through 8 years who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, vaccination providers should discuss with the parents or caregivers the benefits and risks of influenza vaccinations with Afluria before administering the vaccine. Afluria may be used in persons aged \geq 9 years.

§ FluMist is shipped refrigerated and stored in the refrigerator at 35°F–46°F (2°C–8°C) after arrival in the vaccination clinic. The dose is 0.2 mL divided equally between each nostril. Healthcare providers should consult the medical record, when available, to identify children aged 2 through 4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2–4 years should be asked: "In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist.

§§ FluMist is indicated for healthy, non-pregnant persons aged 2 through 49 years. Persons who care for severely immunosuppressed persons who require a protective environment should not receive FluMist given the theoretical risk for transmission of the live-attenuated vaccine virus.

^{*}Vaccination providers should consult Food and Drug Administration-approved prescribing information for 2012-2013 influenza vaccines for the most updated information, including indications, contraindications, and precautions.

^{**}For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.